Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Aldeyra 6.842M share Spot Secondary priced at $9.50 » 05:56
01/14/21
01/14
05:56
01/14/21
05:56
ALDX

Aldeyra

$10.17 /

-0.64 (-5.92%)

The deal size was…

The deal size was increased to $65M in common stock from $50M in common stock. Jefferies and SVB Leerink acted as joint book running managers for the offering.

ShowHide Related Items >><<
ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

  • 14
    Jan
Wednesday
Syndicate
Aldeyra $50M Spot Secondary re-offered at $9.50 » 16:25
01/13/21
01/13
16:25
01/13/21
16:25
ALDX

Aldeyra

$10.17 /

-0.64 (-5.92%)

Jefferies and SVB Leerink…

Jefferies and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
ALDX Aldeyra
$10.17 /

-0.64 (-5.92%)

  • 14
    Jan
Syndicate
Aldeyra announces common stock offering, no amount given » 16:05
01/13/21
01/13
16:05
01/13/21
16:05
ALDX

Aldeyra

$10.16 /

-0.65 (-6.01%)

Aldeyra Therapeutics…

Aldeyra Therapeutics announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Aldeyra, with net proceeds to be used for the continued development of Aldeyra's lead compound, reproxalap, and its other product candidates, as well as for working capital and other general corporate purposes. Jefferies and SVB Leerink are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
ALDX Aldeyra
$10.16 /

-0.65 (-6.01%)

ALDX Aldeyra
$10.16 /

-0.65 (-6.01%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
ALDX Aldeyra
$10.16 /

-0.65 (-6.01%)

Over a week ago
Recommendations
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies » 09:26
01/08/21
01/08
09:26
01/08/21
09:26
ALDX

Aldeyra

$8.45 /

+1.74 (+25.93%)

Jefferies analyst Kelly…

Jefferies analyst Kelly Shi noted that the run-in cohort of a Phase 3 TRANQUILITY trial for reproxalap's dry eye program showed a positive outcome on both symptoms and an alternative sign endpoint, but that the RASP sign-endpoint requires longer time for data analysis. Based on the company's update, she expects positive topline results of the TRANQUILITY study in the first half of 2021, said Shi, who thinks such an event "could trigger +100% share lift." Shi has a Buy rating and $24 price target on Aldeyra, which closed Thursday trading at $8.47.

ShowHide Related Items >><<
ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

Recommendations
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi » 06:37
01/08/21
01/08
06:37
01/08/21
06:37
ALDX

Aldeyra

$8.45 /

+1.74 (+25.93%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz sees "plenty of upside" following yesterday's rally and keeps a Buy rating on Aldeyra Therapeutics with a $22 price target. Data from the Phase 3 TRANQUILITY run-in cohort exceeded expectations, with multiple sign endpoints demonstrating a statistically significant benefit, Nochomovitz tells investors in a research note. The analyst sees the $22 price target as "very achievable," especially in the wake of yesterday's data. Nochomovitz believes the stock offers a buying opportunity despite yesterday's 26% rally.

ShowHide Related Items >><<
ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
ALDX Aldeyra
$8.45 /

+1.74 (+25.93%)

Recommendations
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP » 13:55
01/07/21
01/07
13:55
01/07/21
13:55
ALDX

Aldeyra

$7.73 /

+1.02 (+15.20%)

Alliance Global Partners…

Alliance Global Partners analyst Matt Cross maintained a Buy rating and $32 price target on Aldeyra shares after the company announced "markedly positive" results from the 23-patient run-in portion of the Phase 3 Tranquility study in patients with dry eye disease. Cross says the data further suggests that 2021 may be a very good year for Aldeyra and believes the company is in an "enviable position," as reproxalap has not only confirmed its ability to product statistically significant improvements in ocular redness relative to vehicle in a DED chamber, but also provided the first credible evidence that these effects on a recognized DED sign endpoint are observed within minutes of administration. Further, the analyst believes the dataset has meaningfully de-risked the full Tranquility dataset ahead.

ShowHide Related Items >><<
ALDX Aldeyra
$7.73 /

+1.02 (+15.20%)

ALDX Aldeyra
$7.73 /

+1.02 (+15.20%)

12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
ALDX Aldeyra
$7.73 /

+1.02 (+15.20%)

Hot Stocks
Aldeyra announces top-line results from run-in cohort in Tranquility study » 07:18
01/07/21
01/07
07:18
01/07/21
07:18
ALDX

Aldeyra

$6.71 /

-0.16 (-2.33%)

Aldeyra Therapeutics…

Aldeyra Therapeutics announced positive top-line symptom, redness, and Schirmer's test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease. The double-masked, single-center, parallel-group run-in cohort enrolled 23 patients: 12 patients were randomized to receive 0.25% reproxalap ophthalmic solution and 11 patients were randomized to receive vehicle ophthalmic solution. Patients received four doses one day prior to and two doses on the day of exposure to a 90-minute dry eye chamber with minimal humidity, high airflow, and forced visual tasking. Over all time points in aggregate in the dry eye chamber, reproxalap was observed to be statistically superior to vehicle for the two assessed symptoms, visual analog scale, VAS, ocular dryness score and ocular discomfort score in the run-in cohort of TRANQUILITY. "The symptom improvement observed in the run-in cohort of TRANQUILITY announced today support the first-line potential use of reproxalap in dry eye disease, and represent the first results from an ophthalmic solution for chronic use that demonstrate activity acutely following drug administration," stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. "The activity of reproxalap in reducing ocular redness, initially demonstrated in the allergen chamber Phase 2 clinical trial, was also observed in the dry eye chamber run-in results of TRANQUILITY, and we look forward to initiating enrollment of the main cohort." Among many patients and physicians, current dry eye disease therapies are considered inadequate. Discontinuation rates for lifitegrast and cyclosporine, which currently comprise standard of care, exceed 60% within 12 months

ShowHide Related Items >><<
ALDX Aldeyra
$6.71 /

-0.16 (-2.33%)

ALDX Aldeyra
$6.71 /

-0.16 (-2.33%)

12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
ALDX Aldeyra
$6.71 /

-0.16 (-2.33%)

Hot Stocks
Aldeyra confirms SARS-CoV-2 antiviral activity of ADX-1612 » 08:05
12/22/20
12/22
08:05
12/22/20
08:05
ALDX

Aldeyra

$8.14 /

+0.63 (+8.39%)

Aldeyra Therapeutics…

Aldeyra Therapeutics announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies. The results are derived from an international collaboration with the Max Delbruck Center for Molecular Medicine in the Helmholtz Association in Berlin, Germany, which plans additional studies with colleagues at the Charite - Universitatsmedizin Berlin University Hospital in cell and animal COVID-19 models. "The antiviral and anti-inflammatory activity of ADX-1612 demonstrated in COVID-19 models may be applicable to viral diseases generally," stated Emanuel Wyler, Ph.D., Research Scientist at MDC. "We look forward to continuing our collaboration with Aldeyra as we advance ADX-1612 to additional cell and animal models to further characterize the activity of ADX-1612 in COVID-19 and other viral infections," added Markus Landthaler, Ph.D., Group Leader of the Coronavirus Task Force and the Laboratory for RNA Biology and Post-transcriptional Regulation at MDC. In May 2020, Dr. Wyler and colleagues identified HSP90 as a key antiviral target against SARS-CoV-21 and have confirmed the antiviral activity of ADX-1612, a potent HSP90 inhibitor, reported by Aldeyra earlier this year. Additional reports of the activity of ADX-1612, also known as ganetespib, and other HSP90 inhibitors have been subsequently published by independent laboratories. The anti-inflammatory activity of ADX-1612, as assessed by cytokine transcription in SARS-CoV-2-infected primary human cells, included down-regulation of TNF-alpha, IFN-1beta, IL-6, and a variety of other cytokines and pro-inflammatory mediators.

ShowHide Related Items >><<
ALDX Aldeyra
$8.14 /

+0.63 (+8.39%)

ALDX Aldeyra
$8.14 /

+0.63 (+8.39%)

12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
ALDX Aldeyra
$8.14 /

+0.63 (+8.39%)

Hot Stocks
Aldeyra initiates Phase 2 trials of ADX-629 » 08:10
12/17/20
12/17
08:10
12/17/20
08:10
ALDX

Aldeyra

$7.29 /

+0.42 (+6.11%)

Aldeyra announced the…

Aldeyra announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reactive aldehyde species, or RASP, inhibitor, for the treatment of COVID-19, atopic asthma, and psoriasis as part of a systematic strategy to assess activity across different types of immunological diseases. The Phase 2 clinical trials follow a Phase 1 clinical trial of ADX-629, which demonstrated no treatment-related adverse events at any dose tested, as well as target engagement evidenced by statistically lower RASP levels in drug-treated subjects relative to controls.

ShowHide Related Items >><<
ALDX Aldeyra
$7.29 /

+0.42 (+6.11%)

ALDX Aldeyra
$7.29 /

+0.42 (+6.11%)

12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
ALDX Aldeyra
$7.29 /

+0.42 (+6.11%)

Over a month ago
Initiation
Berenberg starts Aldeyra with Buy, sees near-term catalysts » 07:08
12/16/20
12/16
07:08
12/16/20
07:08
ALDX

Aldeyra

$6.87 /

+0.05 (+0.73%)

Berenberg analyst Esther…

Berenberg analyst Esther Hong initiated coverage of Aldeyra Therapeutics with a Buy rating and $32 price target. Aldeyra has a "broad" pipeline with multiple near-term catalysts for late-stage clinical programs, Hong tells investors in a research note. The company's lead candidate, reproxalap, is in development for the treatment of dry eye disease and allergic conjunctivitis, says the analyst.

ShowHide Related Items >><<
ALDX Aldeyra
$6.87 /

+0.05 (+0.73%)

ALDX Aldeyra
$6.87 /

+0.05 (+0.73%)

12/16/20 Berenberg
Aldeyra initiated with a Buy at Berenberg
11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Jefferies
Aldeyra initiated with a Buy at Jefferies
ALDX Aldeyra
$6.87 /

+0.05 (+0.73%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.